

promoters that operate in opposite directions on the gene. The relationship between the RUR-1 "sense" and "antisense" sequences is made clear in the specification, in Example 1, as is set forth below for the convenience of the Examiner:

Because cDNA I.1 specifically hybridized with cDNA 4.1, the two sequences were compared in more detail, and it was found that the first 595 nucleotides of cDNA I.1 were identical to part of the antisense strand of 4.1. The remaining sequence was not related to cDNA 4.1. To further define the relationship between the two cDNAs, the corresponding genomic sequence was obtained. cDNA 4.1 was used as a probe to screen a phage library constructed with genomic DNA from LE9211-RCC cells. A positive phage was isolated which contained a 14kb insert, which was sequenced in the relevant part. The comparison of the three sequences revealed that cDNA I.1 corresponded to the fully spliced transcript of the gene, whereas cDNA 4.1 corresponded to an aberrant message that starts on the antisense strand of the first intron, is transcribed backwards on the antiparallel strand of exon 1 of cDNA I.1, and ends with a polyadenylation site that is located on the reverse strand of the promoter (Fig. 7). This gene is therefore transcribed in both directions. The gene is referred to as RUR-1, which stands for renal tumor ubiquitous gene encoding a peptide on the reverse strand. The 2.2 kb transcript of RUR-1 corresponding to cDNA I.1 is presumably the normal message of this gene, whereas the RUR-1 message corresponding to cDNA 4.1 appears to result from antisense transcription of the same gene.


Accordingly, Applicants respectfully request reconsideration of the restriction of Group I and Group II claims.

Having made the election of Group II claims for prosecution, the Applicant expressly reserves the right to file one or more divisional or continuing applications on the subject matter of the non-elected claims.

Favorable action is hereby earnestly solicited. Should any questions arise concerning the foregoing, please contact the undersigned at the telephone number listed below.

Respectfully submitted,

Van den Eynde and Boon-Falleur, Applicants


John R. Van Amsterdam, Reg. No. 40,212
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210
Telephone: (617) 720-3500

Docket No. L00461.70099.US
Date: November 5, 2002
x11/11/02